Subjective evaluation by participants
References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1
All medications come from licensed 503A compounding pharmacies, and treatment is available nationwide without insurance or membership fees
The uncontrolled generation of GSSG during oxidative stress can contribute to mitochondrial dysfunction by glutathionylation of target proteins, as described below
For patients with lupus: GLP-1s may calm an overactive immune system